Wedbush Equities Analysts Lift Earnings Estimates for STOK

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Equities researchers at Wedbush boosted their FY2024 earnings estimates for shares of Stoke Therapeutics in a note issued to investors on Tuesday, November 5th. Wedbush analyst L. Chico now anticipates that the company will post earnings per share of ($2.00) for the year, up from their previous estimate of ($2.03). Wedbush has a “Outperform” rating and a $17.00 price objective on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.10) per share. Wedbush also issued estimates for Stoke Therapeutics’ Q3 2025 earnings at ($0.62) EPS, FY2025 earnings at ($2.40) EPS, FY2026 earnings at ($2.51) EPS, FY2027 earnings at ($2.05) EPS and FY2028 earnings at ($0.76) EPS.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.05. The company had revenue of $4.89 million for the quarter, compared to the consensus estimate of $3.46 million. Stoke Therapeutics had a negative net margin of 683.35% and a negative return on equity of 57.89%.

STOK has been the topic of several other research reports. Leerink Partners assumed coverage on shares of Stoke Therapeutics in a report on Monday, October 14th. They issued an “outperform” rating and a $18.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 target price on shares of Stoke Therapeutics in a report on Wednesday. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a report on Wednesday. Finally, Leerink Partnrs raised shares of Stoke Therapeutics to a “strong-buy” rating in a report on Friday, October 11th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Stoke Therapeutics has an average rating of “Buy” and a consensus price target of $20.83.

Stoke Therapeutics Stock Up 0.2 %

Shares of NASDAQ:STOK opened at $13.27 on Friday. The company has a market cap of $698.64 million, a price-to-earnings ratio of -6.09 and a beta of 0.95. The firm’s 50-day simple moving average is $13.24 and its 200-day simple moving average is $13.70. Stoke Therapeutics has a fifty-two week low of $3.77 and a fifty-two week high of $17.58.

Insider Activity at Stoke Therapeutics

In other Stoke Therapeutics news, major shareholder Skorpios Trust sold 1,937,500 shares of Stoke Therapeutics stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $14.05, for a total transaction of $27,221,875.00. Following the completion of the transaction, the insider now owns 8,906,181 shares in the company, valued at approximately $125,131,843.05. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 11.30% of the company’s stock.

Institutional Investors Weigh In On Stoke Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of STOK. Redmile Group LLC grew its holdings in shares of Stoke Therapeutics by 93.2% during the first quarter. Redmile Group LLC now owns 5,073,049 shares of the company’s stock worth $68,486,000 after buying an additional 2,447,543 shares in the last quarter. Lynx1 Capital Management LP grew its holdings in Stoke Therapeutics by 40.3% in the second quarter. Lynx1 Capital Management LP now owns 5,185,191 shares of the company’s stock valued at $70,052,000 after purchasing an additional 1,488,371 shares during the period. Assenagon Asset Management S.A. purchased a new stake in Stoke Therapeutics in the second quarter valued at approximately $19,835,000. Baker BROS. Advisors LP grew its holdings in Stoke Therapeutics by 65.9% in the first quarter. Baker BROS. Advisors LP now owns 3,368,443 shares of the company’s stock valued at $45,474,000 after purchasing an additional 1,338,309 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund grew its holdings in Stoke Therapeutics by 426.1% in the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company’s stock valued at $18,741,000 after purchasing an additional 1,123,500 shares during the period.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.